Speed of response to platinum-based chemotherapy: implications for the management of epithelial ovarian cancer.
Eur J Cancer Clin Oncol
; 23(7): 1071-5, 1987 Jul.
Article
in En
| MEDLINE
| ID: mdl-2444439
ABSTRACT
Seventy-nine patients with evaluable epithelial ovarian cancer following primary laparotomy and treated with one of three primary cis-platinum-containing regimens were studied to determine the rate at which clinical cytoreduction occurred and whether a rapid response to treatment was of prognostic significance by improving progression free interval (PFI) or survival. A rapid response to treatment improved PFI in patients treated with single agent cis-platinum (P = 0.04) and increased survival in patients treated with a sequential cis-platinum based combination regimen (P = 0.03). The rate of cytoreduction was not a significant variable, however, in a multiple regression analysis of prognostic factors. Over 75% of all clinical responses, regardless of the regimen, had begun by the completion of the third course of chemotherapy. We conclude that response to active chemotherapy is a rapid phenomenon in ovarian cancer and this has important implications in both the decision to change drug therapy and the timing of further surgical effort.
Search on Google
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Cisplatin
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Year:
1987
Type:
Article